Effects of ultrafiltration on enoxaparin: An in vitro analysis

Journal of Extra-Corporeal Technology

Volumn 33, Issue 2, 2001, Pages 94-99

  Kohtz, Ryan J ^a   Petterson, Craig M ^a   Mills, Nancy J ^a   Kmiecik, Scott A ^a   Liu, Jun Li ^a   Nichols, Jeffery D ^a   Vaadia, Tal S ^a   Stammers, Alfred H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CPB; Enoxaparin; HIT; Low molecular weight heparin; Ultrafiltration

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; HEAT EXCHANGE; HEMATOCRIT; HEMOCONCENTRATION; HUMAN; IN VITRO STUDY; POTENTIOMETRY; QUANTITATIVE ASSAY; TEMPERATURE; ULTRAFILTRATION; VISCOELASTICITY;

EID: 0034998323     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Speiss BD, Gernsheimer T, Vocelka C, et al. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation. J Cardio Thor Vasc Anesth. 1996;10:918-21.
2. Slocum MM, Adams JG, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg. 1996;23:839-43.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopema in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med. 1995;332:1330-5.
4. Graves EJ: 1989 Summary, National Hospital Discharge Survey. Advance data from vital and health statistics (No. 199). Hyattsville, MD, National Center for Health Statistics. 1999:4-8.
5. Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg. 1984;87.673-7.
6. Zulys V, Teasdalt S, Machel E, et al. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989;71:870-7.
7. Reiss F, Lower C, Seeling C, et al. Recombinant hiradin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man J Thorac Cardiovasc Surg. 1995;110:1-3.
8. Addonizio VP, Fisher CA, Kappa JR, Ellison N, Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374), Surgery. 1987,102:796-807.
9. Frank RD, Farber H, Steffanidis I, Lanzmich R, Kierdorf HP. Hirudin elimination by hemofiltration: A comparative in vitro study of different membranes. Kidney Int Supp. 1999;72:S41-5
10. Bucha E, Kreml R, Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialysers Neph Dialysis Trans. 1999;14:2922-6.
11. Poullis M, Manning R, Haskard D, Taylor K. Reopro removal during cardiopulmonary bypass using a hemoconcentrator. J Thorac Cardiovasc Surg. 1999;117:1032-4.
12. Holt DW, Landis GH, Dumond DA, Hardin SB, Bartosik J, Miller M. Ultrafiltration as an adjunct to cardiopulmonary bypass for total oxygenator volume control J Extra Corp Tech. 1982;14:373-7.
13. Groom RC, Munoz R, McGowen K, et al. Ultrafiltration concentrates heparin. Proceed Am Acad Card Perf. 1996;17:83-5.
14. Ramamurthy N, Baliga N, Wahr J, Schaller U, Yang V, Meyerhoff M. Improved protamine-sensitive membrane electrode for monitoring heparin concentrations in whole blood via protamine titration. Clin Chem. 1998;44:606-13.
15. Altes A, Martino R, Gari M, et al. Heparin-induced thrombocytopenia and heart operation: Management with tedelparin. Ann Thorac Surg. 1995;59:508-9.
16. Robitatlle D, Leclerc JR, Laberge R, et al. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg. 1992,103:597-9.
17. Ganjoo AK, Harloff MG, Johnson WD. Cardiopulmonary bypass for heparin-induced thrombocytopenia: Management with a heparin-bonded circuit and enoxaparin. J Thorac Cardiovasc Surg. 1996;112: 1390-2.
18. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79: 1-17.
19. Lau AH, Kronfol NO. Determinants of drug removal by continuous ultrafiltration. Int J Art Org. 1994;17:373-8.
20. Clar A, Larson DF. Ultrafiltration: Determinants of drug loss and concentration J Extra-Corp Tech 1995;27:158-63.
21. Kessler CM, Esparraguera IM, Jacobs HM. Monitoring the anticoagulant effects of a low molecular weight heparin preparation: Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis. Am J Clin Path. 1995;103:642-8.
22. Koza ML, Messmor HL, Wallock ME, Walenga JM, Pifarre ME. Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery. Thromb Res. 1993;70: 67-76.
23. Brown DM. Perfusing the Jehovah's Witness patient with heparin-induced thrombocytopenia. J Extra Corpor Tech. 1998;30:193-6.